Ultime notizie per ContextLogic (NASDAQ:LOGC) Azioni

ContextLogic

ContextLogic Inc is an online shopping store. The store provides personalized products, clothing products, accessories, gaming products and equipment, cosmetics, plastic products, mobile covers, and other products. Geographically, it derives a majority of its revenue from Europe and also has a presence in North America; South America, and other countries.

ContextLogic Inc

ContextLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.06) by 733.33 percent. The company reported quarterly sales of $7.00 million which beat the analyst consensus estimate of $1.74 million by 302.30 percent. This is a 91.03 percent decrease over sales of $78.00 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

LOGC

ContextLogic Q2 2024 Adj EPS $(0.50) Misses $(0.06) Estimate, Sales $7.00M Beat $1.74M Estimate

<h3>Gainers</h3>
<ul>
<li>JX Luxventure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JXJT#NASDAQ">JXJT</a>) shares increased by 13.3% to $1.7 during Thursday's regular session. The market value of their outstanding shares is at $10.3 million. </li>
<li>Koss (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOSS#NASDAQ">KOSS</a>) shares increased by 9.59% to $11.65. The company's market cap stands at $107.8 million. </li>
<li>Greenlane Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) stock rose 7.27% to $0.29. The company's market cap stands at $1.1 million. </li>
<li>Kirkland's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIRK#NASDAQ">KIRK</a>) shares rose 4.99% to $1.68. The market value of their outstanding shares is at $21.9 million. </li>
<li>Rent the Runway (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENT#NASDAQ">RENT</a>) stock increased by 4.95% to $15.46. The company's market cap stands at $57.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ToughBuilt Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBLT#NASDAQ">TBLT</a>) stock fell 10.8% to $4.47 during Thursday's regular session. The market value of their outstanding shares is at $3.4 million. </li>
<li>BurgerFi International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFI#NASDAQ">BFI</a>) shares declined by 9.16% to $0.17. The company's market cap stands at $4.7 million. </li>
<li>Golden Heaven Group Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) stock fell 4.85% to $0.18. The company's market cap stands at $9.4 million. </li>
<li>ContextLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) shares decreased by 4.6% to $5.49. The company's market cap stands at $134.3 million. </li>
<li>Lead Real Estate Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRE#NASDAQ">LRE</a>) shares decreased by 3.72% to $1.81. The company's market cap stands at $24.6 million. </li>
<li>SRM Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRM#NASDAQ">SRM</a>) stock declined by 3.51% to $1.1. The company's market cap stands at $11.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

GDHG

GNLN

JXJT

KIRK

KOSS

RENT

TBLT

11 Consumer Discretionary Stocks Moving In Thursday's Intraday Session

LogicBio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) reported quarterly losses of $(0.18) per share. This is a 41.94 percent increase over losses of $(0.31) per share from the same period last year.

LogicBio Therapeutics Q3 EPS $(0.18) Up From $(0.31) YoY

On Friday, shares of LogicBio Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/logc#NASDAQ">LOGC</a>) experienced volatile short activity. After the activity, the stock price went up +0% to $2.07.
The overall sentiment for LOGC has been Neutral.
The signal from the volatility alert is trending Bearish. Therefore, the recommendation is to Increase Short Exposure.
The volatility alert was produced on the prior trading date, 11/4/2022 with a volatility change of +102.26%. The current volatility indicator stands at 7.928.
Overview: 
The securities lending volatility indicator is produced by Tidal Markets, in partnership with Benzinga Insights. Securities lending primarily serves the purpose of providing liquidity to short sellers. When unusual activity occurs in the securities lending markets, it acts as an upstream indicator to what is likely to occur downstream in the regular stock market.
Understanding the Volatility Alert: 
Overall sentiment is considered &quot;bear&quot; when broad market activity of the stock has been shown to indicate a negative directional basis, or is considered &quot;bull&quot; when indicating a positive directional basis. The securities lending volatility indicator provides a signal when it detects unusual short activity. Unusual short activity is based off a computer generated algorithmic formula utilizing securities lending trade details such as the volume of shares being shorted, the rate being paid to short the shares, and the type of collateral being posted - amongst other variables. The current volatility is the respective trading day&#39;s calculated securities lending volatility value. The volatility percentage change is the percentage difference in volatility between the two most recent days. The recommendation is a suggestive strategy, inferred from the strength of the Signal Trending, Current Volatility, and Volatility % Change. Recommendations may include, &quot;Strong Buy&quot;, &quot;Strong Sell&quot;, &quot;Increase Short Exposure&quot;, &quot;Decrease Short Exposure&quot;, or &quot;Market Neutral&quot;.
ANY INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE OR IMPLY INVESTMENT ADVICE 
&nbsp;

Penny Stocks

Short Ideas

Trading Ideas

Short Volatility Alert: LogicBio Therapeutics, Inc.

LogicBio Therapeutics Says On Oct. 14, Co. Received Compliance Letter From Nasdaq Notifying That Co.'s Bid Price Deficiency Had Been Cured

<h3>Gainers</h3>
<ul>
<li>LogicBio Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/logc#NASDAQ">LOGC</a>) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca&#39;s subsidiary, Alexion, for $2.07 per share.</li>
<li>FedNat Holding Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fnhc#NASDAQ">FNHC</a>) jumped 308.7% to close at $0.47 after dipping around 28% on Friday.</li>
<li>Oblong, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/oblg#NASDAQ">OBLG</a>) gained 167% to settle at $0.40. Shares of several companies in the technology sector traded higher as stocks rebound following recent weakness.</li>
<li>FingerMotion, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fngr#NASDAQ">FNGR</a>) shares rose 92.9% to close at $6.50 after the stock rose more than 80% Friday.</li>
<li>Wearable Devices Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wlds#NASDAQ">WLDS</a>) gained 48.9% to close at $1.31 after declining around 8% on Friday. Wearable Devices, last week, posted a 1H loss of $0.18 per share.</li>
<li>Flexible Solutions International, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsi#NYSE">FSI</a>) gained 44.2% to close at $2.38. FSI reported termination of merger with Lygos Inc.</li>
<li>Myovant Sciences Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/myov#NYSE">MYOV</a>) shares climbed 36.1% to close at $24.44 after the company received an acquisition offer from Sumitovant Biopharma and Sumitormo Pharma to acquire the company for $22.75 per share in cash.</li>
<li>Lottery.com Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ltry#NASDAQ">LTRY</a>) gained 34% to settle at $0.3015.</li>
<li>Blue Star Foods Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bsfc#NASDAQ">BSFC</a>) jumped 32% to close at $0.8316. Blue Star Foods recently signed a one-year extension to its multi-year supply contract with Sysco Corp.</li>
<li>LiveWire Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lvwr#NYSE">LVWR</a>) climbed 29.5% to close at $9.30.</li>
<li>Engine Gaming and Media, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/game#NASDAQ">GAME</a>) gained 28.9% to close at $0.7262. Engine Gaming&#39;s Frankly Media and Aggregated Media announced a partnership.</li>
<li>Viasat, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vsat#NASDAQ">VSAT</a>) climbed 26.9% to close at $38.37 after the company announced it entered into a definitive agreement to sell its Link 16 Tactical Data Links business to L3Harris Technologies for $1.96 billion.</li>
<li>Energy Vault Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nrgv#NYSE">NRGV</a>) surged 23.1% to settle at $6.50.</li>
<li>MyMD Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mymd#NASDAQ">MYMD</a>) gained 22.6% to close at $3.20.</li>
<li>Companhia de Saneamento B&aacute;sico do Estado de S&atilde;o Paulo &ndash; SABESP (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sbs#NYSE">SBS</a>) gained 22.4% to close at $11.15.</li>
<li>Snow Lake Resources Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/litm#NASDAQ">LITM</a>) surged 22.2% to close at $2.15.</li>
<li>F-star Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fstx#NASDAQ">FSTX</a>) rose 21.7% to settle at $6.23. F-star Therapeutics, in August, posted a Q2 loss of $0.88 per share.</li>
<li>Locafy Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lcfy#NASDAQ">LCFY</a>) gained 20.5% to settle at $0.47.</li>
<li>Isoray, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/isr#NYSE">ISR</a>) jumped 20.4% to close at $0.2769. IsoRay recently announced it entered into a definitive agreement to acquire Viewpoint Molecular Targeting.</li>
<li>Century Aluminum Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cenx#NASDAQ">CENX</a>) gained 18.6% to close at $6.26. Shares of aluminum companies traded higher as the London Metal Exchange considers a potential ban on Russian commodities.</li>
<li>Aditxt, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adtx#NASDAQ">ADTX</a>) climbed 18.6% to close at $4.02.</li>
<li>Athersys, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/athx#NASDAQ">ATHX</a>) gained 18.4% to close at $2.19.</li>
<li>InterDigital, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/idcc#NASDAQ">IDCC</a>) jumped 18.3% to close at $47.81 after the company raised its Q3 sales guidance and entered into a patent license agreement with a major technology company.</li>
<li>Immunovant, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imvt#NASDAQ">IMVT</a>) gained 18.1% to close at $6.59.</li>
<li>Gol Linhas A&eacute;reas Inteligentes S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gol#NYSE">GOL</a>) jumped 16.7% to close at $3.84 as Brazilian President Bolsonaro outperforms polls in the Brazilian runoff election.</li>
<li>Azul S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/azul#NYSE">AZUL</a>) gained 16.3% to close at $9.47 after the Brazilian election resulted in a runoff giving Bolsonaro a chance to maintain the presidency.</li>
<li>Vertiv Holdings Co (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vrt#NYSE">VRT</a>) jumped 15.7% to close at $11.25. Vertiv Holdings Co Chief Executive Officer Rob Johnson will retire from his position due to health reasons, effective December 31, 2022.</li>
<li>Kiora Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kprx#NASDAQ">KPRX</a>) rose 15.6% to close at $7.11.</li>
<li>New Gold Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ngd#NYSE">NGD</a>) gained 14.8% to close at $1.01. RBC Capital upgraded New Gold from Sector Perform to Outperform and raised the price target from $1 to $1.25.</li>
<li>BGC Partners, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bgcp#NASDAQ">BGCP</a>) rose 14.7% to close at $3.60. BGC Partners recently said it expects Q3 sales to be below the midpoint of the range it previously stated.</li>
<li>Avenue Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atxi#NASDAQ">ATXI</a>) rose 14.2% to close at $11.51.</li>
<li>QualTek Services Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qtek#NASDAQ">QTEK</a>) gained 13.9% to close at $2.29.</li>
<li>Coeur Mining, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cde#NYSE">CDE</a>) gained 13.7% to close at $3.89.</li>
<li>Endeavour Silver Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/exk#NYSE">EXK</a>) gained 13.6% to close at $3.43.</li>
<li>Oceaneering International, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/oii#NYSE">OII</a>) jumped 12.9% to close at $8.99. Shares of oil-related stocks traded higher as oil rises amid reports suggesting OPEC+ is considering an oil production cut of 1 million barrels per day.</li>
<li>Color Star Technology Co., Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cscw#NASDAQ">CSCW</a>) gained 12.7% to close at $1.33.</li>
<li>Acorda Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acor#NASDAQ">ACOR</a>) gained 12.7% to close at $0.3370 after gaining 8% on Friday.</li>
<li>Petr&oacute;leo Brasileiro S.A. &ndash; Petrobras (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pbr#NYSE">PBR</a>) rose 12.6% to close at $13.90.</li>
<li>Alcoa Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aa#NYSE">AA</a>) gained 11.1% to close at $37.39.</li>
<li>Anebulo Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aneb#NASDAQ">ANEB</a>) jumped 10.6% to close at $3.0963. Anebulo Pharmaceuticals recently announced interim data from the first two cohorts of Part B of its ongoing Phase 2 trial of ANEB-001 for acute cannabinoid intoxication (ACI).</li>
<li>Tenax Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tenx#NASDAQ">TENX</a>) gained 8.8% to close at $0.1850. Tenax Therapeutics, last month, said it is evaluating alternative strategic paths.</li>
<li>Mondee Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mond#NASDAQ">MOND</a>) gained 8.5% to close at $8.47.</li>
<li>Calithera Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cala#NASDAQ">CALA</a>) gained 8.2% to close at $3.18 after the company announced the FDA granted Fast Track designation for sapanisertib for the treatment of NRF2-mutated squamous lung cancer.</li>
<li>Kosmos Energy Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kos#NYSE">KOS</a>) gained 7.9% to close at $5.58. Shares of several oil stocks traded higher amid an increase in the price of oil as OPEC+ is rumored to be considering a 1M barrel per day oil production cut.</li>
<li>Mesoblast Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meso#NASDAQ">MESO</a>) gained 7.3% to close at $2.73.</li>
<li>United States Steel Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/x#NYSE">X</a>) gained 7% to settle at $19.39.</li>
<li>Kuke Music Holding Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kuke#NYSE">KUKE</a>) gained 6.2% to close at $0.50.</li>
</ul>
&nbsp;
<h3>Losers</h3>
<ul>
<li>Blue Apron Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aprn#NYSE">APRN</a>) fell 45.3% to close at $3.16 on Monday after the company announced an equity distribution agreement allowing the company to sell up to $15 million of stock.</li>
<li>Clene Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clnn#NASDAQ">CLNN</a>) shares fell 28.2% to close at $2.01 after the company released topline results from the Healey ALS Platform trial of CNM-Au8, an investigational gold nanocrystal suspension, in participants with amyotrophic lateral sclerosis (ALS).</li>
<li>Nuwellis, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nuwe#NASDAQ">NUWE</a>) dipped 22.1% to settle at $0.4201 after the company announced results of the AVOID-HF clinical study analysis at the 2022 HFSA meeting, showing a &quot;statistically superior clinical benefit of Aquadex therapy in reducing heart failure events and mortality.&quot;</li>
<li>Timber Pharmaceuticals, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tmbr#NYSE">TMBR</a>) dropped 20.9% to close at $0.0949. Timber Pharmaceuticals reported a $1.3 million registered direct offering.</li>
<li>American Virtual Cloud Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avct#NASDAQ">AVCT</a>) fell 20.6% to close at $2.40. American Virtual Cloud Technologies, on Friday, announced the intent to effect a reverse stock split.</li>
<li>Aura Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aura#NASDAQ">AURA</a>) fell 19.5% to close at $14.59. Aura Biosciences announced interim Phase 2 data evaluating suprachoroidal administration of belzupacap sarotalocan for the first-line treatment of patients with early-stage choroidal melanoma presented at the AAO 2022.</li>
<li>Pharvaris N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/phvs#NASDAQ">PHVS</a>) dropped 19.3% to close at $6.19.</li>
<li>Ecoark Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zest#NASDAQ">ZEST</a>) fell 19.2% to settle at $1.05.</li>
<li>GigaCloud Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gct#NASDAQ">GCT</a>) dropped 18.5% to close at $8.24. Aegis Capital initiated coverage on GigaCloud Tech with a Buy rating and announced a price target of $26.</li>
<li>Adamis Pharmaceuticals Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/admp#NASDAQ">ADMP</a>) dropped 16.8% to close at $0.1651. Adamis Pharmaceuticals announced a review of strategic alternatives.</li>
<li>FaZe Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/faze#NASDAQ">FAZE</a>) declined 15.8% to close at $8.15.</li>
<li>SHF Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/shfs#NASDAQ">SHFS</a>) fell 14.9% to close at $5.90 after dropping 20% on Friday.</li>
<li>Eve Holding, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/evex#NYSE">EVEX</a>) dropped 14.6% to settle at $7.89.</li>
<li>Belite Bio, Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/blte#NASDAQ">BLTE</a>) fell 14% to close at $29.10. Belite Bio presented 12-month interim results of LBS-008 Phase 1b/2 study in adolescent Stargardt disease at the AAO Annual Meeting 2022.</li>
<li>Takung Art Co., Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tkat#NASDAQ">TKAT</a>) declined 13.8% to close at $0.8970.</li>
<li>Hippo Holdings Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hipo#NYSE">HIPO</a>) fell 12.8% to close at $16.16.</li>
<li>Waldencast plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wald#NASDAQ">WALD</a>) fell 12% to close at $8.80.</li>
<li>Apellis Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apls#NASDAQ">APLS</a>) fell 10.6% to close at $61.04.</li>
<li>Tyra Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tyra#NASDAQ">TYRA</a>) fell 10.6% to close at $7.86.</li>
<li>Third Harmonic Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/thrd#NASDAQ">THRD</a>) dropped 10.4% to close at $17.00.</li>
<li>Kintara Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ktra#NASDAQ">KTRA</a>) fell 10.3% to close at $0.0969. Maxim Group recently downgraded Kintara Therapeutics from Buy to Hold.</li>
<li>AMC Entertainment Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ape#NYSE">APE</a>) fell 10% to close at $2.44.</li>
<li>mCloud Technologies Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mcld#NASDAQ">MCLD</a>) dipped 9.3% to settle at $1.36.</li>
<li>Lilium N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lilm#NASDAQ">LILM</a>) dropped 9.2% to close at $2.07. Lilium recently announced partnership with GlobeAir.</li>
<li>Tesla, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) shares fell 8.6% to close at $242.40 after the company reported third-quarter vehicle deliveries below Wall Street expectations. Tesla said it produced 365,923 vehicles in the quarter and delivered 343,830.</li>
<li>Lordstown Motors Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ride#NASDAQ">RIDE</a>) dropped 7.7% to settle at $1.69.</li>
<li>Remitly Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rely#NASDAQ">RELY</a>) fell 6.1% to close at $10.44.</li>
</ul>

Small Cap

Pre-Market Outlook

Markets

ACOR

ADMP

ADTX

ANEB

APLS

APRN

ATHX

ATXI

AURA

AVCT

AZUL

BGCP

BLTE

BSFC

CALA

CENX

CLNN

CSCW

EVEX

FAZE

FNGR

FNHC

FSTX

GAME

HIPO

IDCC

IMVT

Kiora Pharmaceuticals, Inc. - Common Stock

KPRX

Kintara Therapeutics, Inc. - Common Stock

KTRA

KUKE

LCFY

LILM

LITM

LTRY

LVWR

MCLD

MESO

MOND

MyMD Pharmaceuticals, Inc. - Common Stock

MYMD

MYOV

NRGV

NUWE

OBLG

PHVS

QTEK

RELY

Lordstown Motors Corp. - Class A Common Stock

RIDE

Companhia De Saneamento Basico Do Estado De Sao

SHF Holdings, Inc. - Class A Common Stock

SHFS

TENX

THRD

TKAT

TMBR

TSLA

TYRA

VSAT

WALD

WLDS

ZEST

Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite climbing around 270 points on Monday.
The Dow traded up 2.93% to 29,566.07&nbsp;while the NASDAQ rose 2.56% to 10,846.26. The S&amp;P 500 also rose, gaining, 2.85% to 3,687.75.
<a href="https://www.benzinga.com/news/22/10/29113143/nike-lululemon-dicks-sporting-goods-and-other-big-losers-from-friday">Also check this: Nike, Lululemon, Dick&#39;s Sporting Goods And Other Big Losers From Friday </a>

Leading and Lagging Sectors

Energy shares jumped by 4.9% on Monday. Leading the <a href='https://www.benzinga.com/money/best-sectors-to-invest-in-right-now/'>sector</a> was strength from Ultrapar Participa&ccedil;&otilde;es S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ugp#NYSE">UGP</a>) and Amplify Energy Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ampy#NYSE">AMPY</a>).

In trading on Monday, consumer discretionary shares rose by just 0.2%.

Top Headline

The ISM manufacturing PMI unexpectedly dropped to 50.9 in September, compared with 52.8 in the previous month. However, analysts were expecting a reading of 52.2.
&nbsp;
Equities Trading UP
&nbsp;
<ul>
<li>LogicBio Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/logc#NASDAQ">LOGC</a>) shares shot up 644% to $2.0264 after the company announced it will be acquired by AstraZeneca&#39;s subsidiary, Alexion, for $2.07 per share.</li>
<li>Shares of Flexible Solutions International, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsi#NYSE">FSI</a>) got a boost, shooting 39% to $2.3016. FSI reported termination of merger with Lygos Inc.</li>
<li>Myovant Sciences Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/myov#NYSE">MYOV</a>) shares were also up, gaining 38% to $24.84 after the company received an acquisition offer from Sumitovant Biopharma and Sumitormo Pharma to acquire the company for $22.75 per share in cash.</li>
</ul>

&nbsp;
Equities Trading DOWN
<ul>
<li>Clene Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clnn#NASDAQ">CLNN</a>) shares tumbled 29% to $1.9770 after the company released topline results from the Healey ALS Platform trial of CNM-Au8, an investigational gold nanocrystal suspension, in participants with amyotrophic lateral sclerosis (ALS).</li>
<li>Shares of Blue Apron Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aprn#NYSE">APRN</a>) were down 40% to $3.4808 after the company announced an equity distribution agreement allowing the company to sell up to $15 million of stock.</li>
<li>Timber Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmbr#NASDAQ">TMBR</a>) was down, falling 20% to $0.0961 after the company announced a $1.3 million registered direct offering.</li>
</ul>


<a href="https://www.benzinga.com/news/22/10/29112813/dow-tumbles-500-points-volatility-in-markets-increases-further">Also check out: Dow Tumbles 500 Points, Volatility In Markets Increases Further</a>

Commodities
In commodity news, oil traded up 5.1% to $83.53, while gold traded up 1.8% at $1,701.70.

Silver traded up 8.2% to $20.605 on Monday while copper fell 0.1% to $3.4115.

Euro zone

European shares closed higher today. The eurozone&rsquo;s STOXX 600 gained 0.77%, London&rsquo;s FTSE 100 rose 0.22% while Spain&rsquo;s IBEX 35 Index rose 1.29%. The German DAX gained 0.79%, French CAC 40 gained 0.55% and Italy&rsquo;s FTSE MIB Index gained 1.57%.
The S&amp;P Global Eurozone manufacturing PMI was revised lower to 48.4 in September compared to a preliminary reading of 48.5. The S&amp;P Global/CIPS manufacturing PMI for UK was revised lower to 48.4 in September from a preliminary level of 48.5, while German manufacturing PMI fell to 47.8 in September from a preliminary reading of 48.3.
The S&amp;P Global French manufacturing PMI fell to 47.7 in September versus 50.6 in the previous month, while Italian manufacturing PMI rose to 48.3 in September from the 48 a month ago. The S&amp;P Global manufacturing PMI for Spain dropped to 49 in September from 49.9 in the prior month.

Economics
&nbsp;
<ul>
<li>The final reading of S&amp;P Global manufacturing PMI was revised higher to 52 for September from preliminary reading of 51.8 and up from 51.5 in August.</li>
<li>The ISM manufacturing PMI unexpectedly dropped to 50.9 in September, compared with 52.8 in the previous month. However, analysts were expecting a reading of 52.2.</li>
<li>Construction spending in the US dropped by 0.7% from the prior month to an annual rate of $1.78 billion in August.</li>
</ul>


<a href="https://www.benzinga.com/news/22/10/29113844/investor-fear-eases-slightly-despite-dow-dipping-around-9-in-september">Check out this: Investor Fear Eases Slightly Despite Dow Dipping Around 9% In September</a>

COVID-19 Update
The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 98,254,650 cases with around 1,084,890 deaths. India confirmed a total of at least 44,597,490 cases and 528,700 deaths, while France reported over 35,475,260 COVID-19 cases with 155,110 deaths. In total, there were at least 623,554,200 cases of COVID-19 worldwide with more than 6,550,950 deaths.

Eurozone

Commodities

Global

Intraday Update

AMPY

Nasdaq Jumps 270 Points; Silver Surges Over 8%

<h3>Gainers</h3>
<ul>
<li>LogicBio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) shares increased by 641.3% to $2.02 during Monday&#39;s regular session. The current volume of 10.3 million shares is 5450.9% of LogicBio Therapeutics&#39;s average full-day volume over the last 100 days (last updated at 13:30 EST). The company&#39;s market cap stands at $66.5 million.</li>
<li>Myovant Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYOV#NYSE">MYOV</a>) shares moved upwards by 38.78% to $24.93. Trading volume for Myovant Sciences&#39;s stock is 6.3 million as of 13:30 EST. This is 853.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.3 billion.</li>
<li>Avenue Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) shares rose 31.16% to $13.22. The current volume of 13.8 million shares is 784.6% of Avenue Therapeutics&#39;s average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $19.5 million.</li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) shares increased by 24.37% to $7.79. The company&#39;s market cap stands at $58.5 million.</li>
<li>Lucira Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LHDX#NASDAQ">LHDX</a>) shares moved upwards by 21.38% to $1.29. As of 13:30 EST, Lucira Health&#39;s stock is trading at a volume of 98.0K, which is 190.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $51.6 million.</li>
<li>Anebulo Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANEB#NASDAQ">ANEB</a>) stock rose 20.93% to $3.39. The market value of their outstanding shares is at $79.1 million.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Clene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNN#NASDAQ">CLNN</a>) shares declined by 30.4% to $1.95 during Monday&#39;s regular session. Trading volume for this security as of 13:30 EST is 2.7 million, which is 236.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $123.8 million.</li>
<li>Belite Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLTE#NASDAQ">BLTE</a>) shares fell 19.71% to $26.94. As of 13:30 EST, this security is trading at a volume of 70.5K shares, making up 111.7% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $669.9 million.</li>
<li>Adamis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMP#NASDAQ">ADMP</a>) shares declined by 16.53% to $0.17. Trading volume for this security as of 13:30 EST is 2.3 million, which is 331.0% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $24.8 million.</li>
<li>Aura Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AURA#NASDAQ">AURA</a>) stock decreased by 16.01% to $15.22. As of 13:30 EST, Aura Biosciences&#39;s stock is trading at a volume of 92.6K, which is 130.8% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $445.5 million.</li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock fell 14.38% to $3.93. As of 13:30 EST, Shuttle Pharmaceuticals&#39;s stock is trading at a volume of 694.1K, which is 13.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $52.9 million.</li>
<li>Kintara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) shares decreased by 14.08% to $0.09. As of 13:30 EST, Kintara Therapeutics&#39;s stock is trading at a volume of 3.9 million, which is 172.6% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $7.4 million. As per the news, the Q4 earnings report came out 4 days ago. See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

BNOX

LHDX

SHPH

12 Health Care Stocks Moving In Monday's Intraday Session

LogicBio Therapeutics&#39;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) short percent of float has fallen 62.5% since its last report. The company recently reported that it has 29 thousand shares sold short, which is 0.12% of all regular shares that are available for trading. Based on its trading volume, it would take traders 0.2 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>LogicBio Therapeutics Short Interest Graph (3 Months)</h3>
<img alt="short_fig" src="https://www.benzinga.com/files/images/story/2022/1664816450_0_0.png" />
As you can see from the chart above the percentage of shares that are sold short for LogicBio Therapeutics has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing LogicBio Therapeutics&#39;s Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company&#39;s peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company&#39;s peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, LogicBio Therapeutics&#39;s peer group average for short interest as a percentage of float is 8.05%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>.
This article was generated by Benzinga&#39;s automated content engine and was reviewed by an editor.

Short Sellers

Looking Into LogicBio Therapeutics's Recent Short Interest

<h3>Gainers</h3>
<ul>
<li>LogicBio Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/logc#NASDAQ">LOGC</a>) gained 641% to $2.0207 after the company announced it will be acquired by AstraZeneca&#39;s subsidiary, Alexion, for $2.07 per share.</li>
<li>FedNat Holding Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fnhc#NASDAQ">FNHC</a>) jumped 223% to $0.3725 after dipping around 28% on Friday.</li>
<li>FingerMotion, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fngr#NASDAQ">FNGR</a>) shares gained 63.3% to $5.50 after the stock rose more than 80% Friday.</li>
<li>Avenue Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atxi#NASDAQ">ATXI</a>) gained 47.1% to $14.83.</li>
<li>Myovant Sciences Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/myov#NYSE">MYOV</a>) shares gained 36% to $24.43 after the company received an acquisition offer from Sumitovant Biopharma and Sumitormo Pharma to acquire the company for $22.75 per share in cash.</li>
<li>Wearable Devices Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wlds#NASDAQ">WLDS</a>) climbed 33% to $1.1701 after declining around 8% on Friday. Wearable Devices, last week, posted a 1H loss of $0.18 per share.</li>
<li>Color Star Technology Co., Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cscw#NASDAQ">CSCW</a>) rose 32% to $1.56.</li>
<li>Viasat, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vsat#NASDAQ">VSAT</a>) gained 27.3% to $38.47 after the company announced it entered into a definitive agreement to sell its Link 16 Tactical Data Links business to L3Harris Technologies for $1.96 billion.</li>
<li>Flexible Solutions International, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsi#NYSE">FSI</a>) rose 25.7% to $2.0736. FSI reported termination of merger with Lygos Inc.</li>
<li>Bionomics Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bnox#NASDAQ">BNOX</a>) gained 24.4% to $7.79.</li>
<li>Anebulo Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aneb#NASDAQ">ANEB</a>) jumped 20.9% to $3.3861. Anebulo Pharmaceuticals recently announced interim data from the first two cohorts of Part B of its ongoing Phase 2 trial of ANEB-001 for acute cannabinoid intoxication (ACI).</li>
<li>Versus Systems Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vs#NASDAQ">VS</a>) gained 20.5% to $0.2254.</li>
<li>LiveWire Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lvwr#NYSE">LVWR</a>) rose 20.3% to $8.64.</li>
<li>Companhia de Saneamento B&aacute;sico do Estado de S&atilde;o Paulo &ndash; SABESP (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sbs#NYSE">SBS</a>) gained 20.2% to $10.95.</li>
<li>Kuke Music Holding Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kuke#NYSE">KUKE</a>) jumped 19.9% to $0.5645.</li>
<li>Tenax Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tenx#NASDAQ">TENX</a>) gained 19.4% to $0.2030. Tenax Therapeutics, last month, said it is evaluating alternative strategic paths.</li>
<li>Calithera Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cala#NASDAQ">CALA</a>) climbed 18.5% to $3.4876 after the company announced the FDA granted Fast Track designation for sapanisertib for the treatment of NRF2-mutated squamous lung cancer.</li>
<li>Acorda Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acor#NASDAQ">ACOR</a>) rose 16.7% to $0.3490 after gaining 8% on Friday.</li>
<li>QualTek Services Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qtek#NASDAQ">QTEK</a>) gained 16.3% to $2.33.</li>
<li>Freight Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/frgt#NASDAQ">FRGT</a>) climbed 15.6% to $0.59.</li>
<li>New Gold Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ngd#NYSE">NGD</a>) gained 14.5% to $1.0087. RBC Capital upgraded New Gold from Sector Perform to Outperform and raised the price target from $1 to $1.25.</li>
<li>LiveWire Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lvwr#NYSE">LVWR</a>) surged 13.7% to $8.17.</li>
<li>InterDigital, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/idcc#NASDAQ">IDCC</a>) jumped 13.8% to $46.02 after the company raised its Q3 sales guidance and entered into a patent license agreement with a major technology company.</li>
<li>Coeur Mining, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cde#NYSE">CDE</a>) gained 13.7% to $3.89.</li>
<li>Vertiv Holdings Co (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vrt#NYSE">VRT</a>) jumped 13% to $11.02 Vertiv Holdings Co Chief Executive Officer Rob Johnson will retire from his position due to health reasons, effective December 31, 2022.</li>
<li>Atlis Motor Vehicles, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amv#NASDAQ">AMV</a>) rose 12.8% to $23.00 after dropping around 40% on Friday.</li>
<li>Mesoblast Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meso#NASDAQ">MESO</a>) jumped 12% to $2.85.</li>
<li>Petr&oacute;leo Brasileiro S.A. &ndash; Petrobras (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pbr#NYSE">PBR</a>) rose 11.9% to $13.81.</li>
<li>Mondee Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mond#NASDAQ">MOND</a>) fell 11.7% to $8.73.</li>
<li>Aditxt, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adtx#NASDAQ">ADTX</a>) gained 10% to $3.70.</li>
<li>Kosmos Energy Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kos#NYSE">KOS</a>) jumped 9.3% to $5.65. Shares of several oil stocks traded higher amid an increase in the price of oil as OPEC+ is rumored to be considering a ~1M barrel per day oil production cut.</li>
<li>Alcoa Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aa#NYSE">AA</a>) gained 8.5% to $36.52.</li>
<li>United States Steel Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/x#NYSE">X</a>) jumped 6% to $19.20.</li>
</ul>
<h3>
Losers</h3>
<ul>
<li>Blue Apron Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aprn#NYSE">APRN</a>) dropped 35% to $3.76 after the company announced an equity distribution agreement allowing the company to sell up to $15 million of stock.</li>
<li>Clene Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clnn#NASDAQ">CLNN</a>) shares dipped 31.4% to $1.92 after the company released topline results from the Healey ALS Platform trial of CNM-Au8, an investigational gold nanocrystal suspension, in participants with amyotrophic lateral sclerosis (ALS).</li>
<li>American Virtual Cloud Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avct#NASDAQ">AVCT</a>) fell 31.2% to $2.0812. American Virtual Cloud Technologies, on Friday, announced the intent to effect a reverse stock split.</li>
<li>Timber Pharmaceuticals, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tmbr#NYSE">TMBR</a>) fell 23.3% to $0.0920. Timber Pharmaceuticals reported a $1.3 million registered direct offering.</li>
<li>Belite Bio, Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/blte#NASDAQ">BLTE</a>) dropped 20.8% to $26.80. Belite Bio presented 12-month interim results of LBS-008 Phase 1b/2 study in adolescent Stargardt disease at the AAO Annual Meeting 2022.</li>
<li>Waldencast plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wald#NASDAQ">WALD</a>) dropped 15% to $8.50.</li>
<li>FaZe Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/faze#NASDAQ">FAZE</a>) declined 15% to $8.23.</li>
<li>SHF Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/shfs#NASDAQ">SHFS</a>) fell 14% to $5.96 after dropping 20% on Friday.</li>
<li>Takung Art Co., Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tkat#NASDAQ">TKAT</a>) declined 14% to $0.8949.</li>
<li>Lilium N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lilm#NASDAQ">LILM</a>) dropped 12.9% to $1.9850. Lilium recently announced partnership with GlobeAir.</li>
<li>Apellis Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apls#NASDAQ">APLS</a>) fell 12.1% to $60.03.</li>
<li>Aura Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aura#NASDAQ">AURA</a>) fell 11.7% to $16.00. Aura Biosciences announced interim Phase 2 data evaluating suprachoroidal administration of belzupacap sarotalocan for the first-line treatment of patients with early-stage choroidal melanoma presented at the AAO 2022.</li>
<li>Tyra Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tyra#NASDAQ">TYRA</a>) dropped 11.5% to $7.78.</li>
<li>Lion Group Holding Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lghl#NASDAQ">LGHL</a>) fell 11% to $0.89.</li>
<li>Hippo Holdings Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hipo#NYSE">HIPO</a>) declined 9.7% to $16.72.</li>
<li>Kintara Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ktra#NASDAQ">KTRA</a>) dropped 8.2% to $0.0991. Maxim Group recently downgraded Kintara Therapeutics from Buy to Hold.</li>
<li>Remitly Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rely#NASDAQ">RELY</a>) dipped 7.8% to $10.25.</li>
<li>SAI.TECH Global Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sai#NASDAQ">SAI</a>) fell 7.3% to $3.0050 after jumping 43% on Friday.</li>
<li>Tesla, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) shares fell 7.2% to $246.09 after the company reported third-quarter vehicle deliveries below Wall Street expectations. Tesla said it produced 365,923 vehicles in the quarter and delivered 343,830.</li>
</ul>

Alternative Asset Management Acquisition Corp

FRGT

LGHL

Why Tesla Shares Are Trading Lower By Over 7%, Here Are 52 Stocks Moving In Monday's Mid-Day Session

U.S. stocks extended gains midway through trading, with the Dow Jones gaining more than 600 points on Monday.
The Dow traded up 2.17% to 29,349.33 while the NASDAQ rose 1.72% to 10,757.76. The S&amp;P 500 also rose, gaining, 2.03% to 3,658.58.
<a href="https://www.benzinga.com/news/22/10/29113143/nike-lululemon-dicks-sporting-goods-and-other-big-losers-from-friday">Also check this: Nike, Lululemon, Dick&#39;s Sporting Goods And Other Big Losers From Friday </a>

Leading and Lagging Sectors

Energy shares jumped by 4.4% on Monday. Leading the <a href='https://www.benzinga.com/money/best-sectors-to-invest-in-right-now/'>sector</a> was strength from Ultrapar Participa&ccedil;&otilde;es S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ugp#NYSE">UGP</a>) and Petr&oacute;leo Brasileiro S.A. - Petrobras (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pbr#NYSE">PBR</a>).

In trading on Monday, consumer discretionary shares rose by just 0.1%.

Top Headline

The ISM manufacturing PMI unexpectedly dropped to 50.9 in September, compared with 52.8 in the previous month. However, analysts were expecting a reading of 52.2.
&nbsp;
Equities Trading UP
&nbsp;
<ul>
<li>LogicBio Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/logc#NASDAQ">LOGC</a>) shares shot up 641% to $2.0202 after the company announced it will be acquired by AstraZeneca&#39;s subsidiary, Alexion, for $2.07 per share.</li>
<li>Shares of Viasat, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vsat#NASDAQ">VSAT</a>) got a boost, shooting 42% to $42.84 after the company announced it entered into a definitive agreement to sell its Link 16 Tactical Data Links business to L3Harris Technologies for $1.96 billion.</li>
<li>Myovant Sciences Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/myov#NYSE">MYOV</a>) shares were also up, gaining 37% to $24.53 after the company received an acquisition offer from Sumitovant Biopharma and Sumitormo Pharma to acquire the company for $22.75 per share in cash.</li>
</ul>

&nbsp;
Equities Trading DOWN
<ul>
<li>Clene Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clnn#NASDAQ">CLNN</a>) shares tumbled 34% to $1.8350 after the company released topline results from the Healey ALS Platform trial of CNM-Au8, an investigational gold nanocrystal suspension, in participants with amyotrophic lateral sclerosis (ALS).</li>
<li>Shares of Blue Apron Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aprn#NYSE">APRN</a>) were down 32% to $3.93 after the company announced an equity distribution agreement allowing the company to sell up to $15 million of stock.</li>
<li>Timber Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmbr#NASDAQ">TMBR</a>) was down, falling 23% to $0.0930 after the company announced a $1.3 million registered direct offering.</li>
</ul>


<a href="https://www.benzinga.com/news/22/10/29112813/dow-tumbles-500-points-volatility-in-markets-increases-further">Also check out: Dow Tumbles 500 Points, Volatility In Markets Increases Further</a>

Commodities
In commodity news, oil traded up 5.5% to $83.84, while gold traded up 1.3% at $1,693.70.

Silver traded up 7.2% to $20.41 on Monday while copper rose 0.2% to $3.4205.

Euro zone

European shares were higher today. The eurozone&rsquo;s STOXX 600 gained 0.77%, London&rsquo;s FTSE 100 rose 0.36% while Spain&rsquo;s IBEX 35 Index rose 1.21%. The German DAX gained 0.81%, French CAC 40 gained 0.46% and Italy&rsquo;s FTSE MIB Index gained 1.38%.
The S&amp;P Global Eurozone manufacturing PMI was revised lower to 48.4 in September compared to a preliminary reading of 48.5. The S&amp;P Global/CIPS manufacturing PMI for UK was revised lower to 48.4 in September from a preliminary level of 48.5, while German manufacturing PMI fell to 47.8 in September from a preliminary reading of 48.3.
The S&amp;P Global French manufacturing PMI fell to 47.7 in September versus 50.6 in the previous month, while Italian manufacturing PMI rose to 48.3 in September from the 48 a month ago. The S&amp;P Global manufacturing PMI for Spain dropped to 49 in September from 49.9 in the prior month.

Economics
&nbsp;
<ul>
<li>The final reading of S&amp;P Global manufacturing PMI was revised higher to 52 for September from preliminary reading of 51.8 and up from 51.5 in August.</li>
<li>The ISM manufacturing PMI unexpectedly dropped to 50.9 in September, compared with 52.8 in the previous month. However, analysts were expecting a reading of 52.2.</li>
<li>Construction spending in the US dropped by 0.7% from the prior month to an annual rate of $1.78 billion in August.</li>
<li>Kansas City Federal Reserve Bank President Esther George will speak at 2:15 p.m. ET.</li>
</ul>

<a href="https://www.benzinga.com/news/22/10/29113844/investor-fear-eases-slightly-despite-dow-dipping-around-9-in-september">Check out this: Investor Fear Eases Slightly Despite Dow Dipping Around 9% In September</a>

COVID-19 Update
The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 98,254,650 cases with around 1,084,890 deaths. India confirmed a total of at least 44,597,490 cases and 528,700 deaths, while France reported over 35,475,260 COVID-19 cases with 155,110 deaths. In total, there were at least 623,554,200 cases of COVID-19 worldwide with more than 6,550,950 deaths.

S&P 500 Surges 2%; Crude Oil Rises Sharply

<h3>Gainers</h3>
<ul>
<li>LogicBio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) shares moved upwards by 641.3% to $2.02 during Monday&#39;s pre-market session. The company&#39;s market cap stands at $66.5 million.</li>
<li>Myovant Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYOV#NYSE">MYOV</a>) stock moved upwards by 31.68% to $23.65. The company&#39;s market cap stands at $2.2 billion.</li>
<li>Acorda Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOR#NASDAQ">ACOR</a>) shares moved upwards by 20.36% to $0.36. The company&#39;s market cap stands at $8.7 million.</li>
<li>NeuBase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBSE#NASDAQ">NBSE</a>) shares moved upwards by 20.12% to $0.47. The company&#39;s market cap stands at $15.3 million.</li>
<li>Zynerba Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYNE#NASDAQ">ZYNE</a>) stock rose 19.79% to $0.88. The market value of their outstanding shares is at $40.1 million.</li>
<li>GBS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBS#NASDAQ">GBS</a>) stock moved upwards by 19.04% to $0.5. The company&#39;s market cap stands at $7.4 million.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Clene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNN#NASDAQ">CLNN</a>) stock declined by 13.2% to $2.43 during Monday&#39;s pre-market session. The market value of their outstanding shares is at $154.3 million.</li>
<li>Ainos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIMD#NASDAQ">AIMD</a>) stock fell 9.53% to $1.71. The company&#39;s market cap stands at $33.3 million.</li>
<li>Alector (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALEC#NASDAQ">ALEC</a>) stock declined by 8.04% to $8.7. The company&#39;s market cap stands at $718.3 million.</li>
<li>Orchard Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORTX#NASDAQ">ORTX</a>) shares declined by 8.0% to $0.46. The market value of their outstanding shares is at $58.1 million.</li>
<li>GreenLight Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRNA#NASDAQ">GRNA</a>) shares declined by 7.33% to $2.15. The company&#39;s market cap stands at $264.8 million.</li>
<li>Medigus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGS#NASDAQ">MDGS</a>) stock declined by 7.08% to $0.51. The company&#39;s market cap stands at $12.5 million. See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

AIMD

ALEC

GRNA

MDGS

NBSE

ORTX

ZYNE

12 Health Care Stocks Moving In Monday's Pre-Market Session

LogicBio Therapeutics&nbsp;Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/logc#NASDAQ">LOGC</a>) shares are trading higher Monday after the company announced it will be acquired by&nbsp;AstraZeneca PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/azn#NASDAQ">AZN</a>) subsidiary&nbsp;Alexion for $2.07 per share.&nbsp;
The proposed acquisition aims to accelerate Alexion&#39;s growth in genomic medicines through LogicBio&#39;s unique technology, experienced rare disease R&amp;D team&nbsp;and expertise in pre-clinical development.
LogicBio has developed technology platforms for the delivery and insertion of genes to address genetic diseases, as well as a platform designed to improve viral vector manufacturing processes. The companies&nbsp;expect&nbsp;these platforms to&nbsp;drive future scientific possibilities.
&quot;Through this acquisition, we strive to accelerate our research in gene editing and AAV capsid development and together move the field of genomic medicine forward,&quot; said&nbsp;Fred Chereau, president and CEO of&nbsp;LogicBio.
Both boards have unanimously approved the transaction. Alexion said it expects the deal to close in four to six weeks.
LogicBio&nbsp;is a clinical-stage genetic medicine company pioneering genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood.&nbsp;
See Also:&nbsp;<a href="https://www.benzinga.com/news/22/10/29114610/s-p-dow-futures-rise-in-new-trading-week-putting-behind-economic-worries-tesla-credit-suisse-energy">S&amp;P 500, Dow Futures Begin Week On Upbeat Note But Credit Suisse Scare Gives Investors Jitters</a>
LOGC Price Action: LogicBio has a 52-week high of $2.53 and a 52-week low of 25 cents.
The stock was up 641.3% at $2.02 at time of publication, according to&nbsp;<a href="https://benzinga.grsm.io/gxjhpowx7zks">Benzinga Pro</a>.
Photo:&nbsp;<a href="https://pixabay.com/users/kkolosov-2105326/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=2030265">Konstantin Kolosov</a>&nbsp;from Pixabay.

Why LogicBio Therapeutics Stock Is Soaring Today

WIIM

LogicBio shares are trading higher after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share.

<ul>
<li>AstraZeneca Plc&#39;s&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/azn#NASDAQ">AZN</a>) subsidiary, Alexion, has&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/22/10/n29114758/alexion-astrazeneca-rare-disease-to-acquire-logicbio-therapeutics-to-accelerate-growth-in-genomic-" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">agreed to acquire</a>&nbsp;LogicBio Therapeutics Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/logc#NASDAQ">LOGC</a>) for $2.07 per share. Both boards have unanimously approved the transaction.&nbsp;</li>
<li>Alexion plans to close the deal in four to six weeks, subject to the tender of at least a majority of the outstanding shares of LogicBio common stock.</li>
<li>It plans to retain LogicBio employees at their current location.</li>
<li>Also Read:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/22/10/n29114758/alexion-astrazeneca-rare-disease-to-acquire-logicbio-therapeutics-to-accelerate-growth-in-genomic-" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">LogicBio Therapeutics Shares Skyrocket As FDA Lifts Clinical Hold On Its Pediatric Trial</a>.</li>
<li>The proposed acquisition brings LogicBio&#39;s unique technology, experienced rare disease R&amp;D team, and expertise in pre-clinical development to support Alexion&#39;s growth in genomic medicines.</li>
<li>Fred Chereau, President and Chief Executive Officer, LogicBio, said, &quot;Through this acquisition, we strive to accelerate our research in gene editing and AAV capsid development and together move the field of genomic medicine forward.&quot;</li>
<li>LogicBio has developed technology platforms for the delivery and insertion of genes to address genetic diseases and a platform designed to improve viral vector manufacturing processes.&nbsp;</li>
<li>Price Action:&nbsp;LOGC shares are up 633.9% at $2.00 during the premarket session on the last check Monday.</li>
</ul>

Biotech

Large Cap

Health Care

General

AZNCF

Why Are LogicBio Therapeutics Shares Skyrocketing Today?

Alexion, AstraZeneca Rare Disease To Acquire LogicBio Therapeutics For $2.07/Share

Single intravenous administration of mLB-001 in neonatal or adult MMA mice correlated with prevention of severe weight loss and mortality when challenged with a high protein diet.
LEXINGTON, Mass., Sept. 21, 2022 /PRNewswire/ -- LogicBio Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>), a clinical-stage genetic medicine company, today announced that results from the company&#39;s preclinical research study entitled &quot;Novel AAV-mediated genome editing therapy prevents metabolic decompensation in a mouse model of methylmalonic acidemia&quot; have been published in the peer-reviewed journal PLOS ONE.
MMA is a metabolic disorder most commonly caused by mutations in the methylmalonyl-CoA mutase (MMUT) gene. Patients with MMUT deficiency are currently treated with strict life-long dietary management to mitigate acute illness that worsens the patient&#39;s basal condition, particularly with respect to metabolic brain injury. Early-stage research has indicated that restoration of Mmut enzymatic activity by gene addition mediated by recombinant adeno-associated virus (rAAV) could be a promising approach in the treatment of MMUT deficiency in pediatric patients.
In the study, researchers developed a novel protein-controlled diet regimen in a MMUT deficient mouse model of MMA that mimics the metabolic crises that MMA patients experience. Mice were treated with a single administration of mLB-001, a nuclease-free, promoterless recombinant AAV vector designed based on LogicBio&#39;s proprietary GeneRide&reg; platform to deliver the mouse MMUT into the endogenous albumin locus. Mice deficient in MMUT that were treated with the Generide AAV vector had attenuated body weight loss and were protected from mortality when challenged with a high protein diet.
GeneRide-edited hepatocytes also expressed functional MMUT protein and expanded over time in the MMUT deficient mice, suggesting a selective growth advantage over the diseased cells. The expansion of the edited cells was detected over time in the MMA mice by measuring increasing levels of Alb-2A, the same technology-specific biomarker that is being used in LogicBio&#39;s SUNRISE trial, a first-in-human, open-label, multi-center, Phase 1/2 clinical trial designed to assess the safety, tolerability, and preliminary efficacy of a single intravenous infusion of LB-001 in pediatric patients with MMA.
&quot;There are no approved therapies to treat the underlying cause of MMUT deficiency. Currently, pediatric patients are managed with strict life-long dietary restrictions designed to help mitigate acute illness that worsens the patient&#39;s basal condition, particularly with respect to metabolic brain injury,&quot; said Mariana Nacht, chief scientific officer at LogicBio. &quot;These new preclinical results provide strong additional support for the continued development of LB-001 in this indication with the potential to deliver significant benefits to pediatric patients.&quot;
To access the full article, click <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3654218-1&amp;h=1197869296&amp;u=https%3A%2F%2Fjournals.plos.org%2Fplosone%2Farticle%3Fid%3D10.1371%2Fjournal.pone.0274774&amp;a=here" target="_blank">here</a>.&nbsp;

LogicBio Therapeutics Announces Pre-Clinical Results For mLB-001 Published In Peer-reviewed Journal PLOS ONE

LogicBio Therapeutics On Sept. 15, Co. Received Formal Notice From Nasdaq Staff Indicating That Staff Had Determined To Delist Co.'s Securities, Co. Says Intends To Timely Request A Hearing Before Nasdaq Hearings Panel

<h3>Gainers</h3>
<ul>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) stock increased by 10.1% to $0.39 during Monday's after-market session. The company's market cap stands at $1.3 million. </li>
<li>Avenue Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) shares rose 8.41% to $0.23. Today's trading volume for this security ended up closing at 60.7K shares, which is 4.3 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $5.1 million. </li>
<li>Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) shares moved upwards by 7.71% to $0.6. The market value of their outstanding shares is at $53.1 million. </li>
<li>BIMI Intl Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIMI#NASDAQ">BIMI</a>) shares moved upwards by 7.61% to $0.39. The market value of their outstanding shares is at $14.4 million. </li>
<li>Change Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHNG#NASDAQ">CHNG</a>) stock moved upwards by 7.57% to $27.4. Change Healthcare's trading volume hit 1.3 million shares by close, accounting for 49.8% of its average volume over the last 100 days. The market value of their outstanding shares is at $8.9 billion. </li>
<li>Applied Genetic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGTC#NASDAQ">AGTC</a>) shares moved upwards by 6.67% to $0.41. The market value of their outstanding shares is at $27.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Virios Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRI#NASDAQ">VIRI</a>) shares fell 15.0% to $1.7 during Monday's after-market session. This security traded at a volume of 694.7K shares come close, making up 2485.4% of its average volume over the last 100 days. The company's market cap stands at $14.1 million. </li>
<li>LogicBio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) stock fell 9.74% to $0.34. The market value of their outstanding shares is at $11.3 million. </li>
<li>Calyxt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLXT#NASDAQ">CLXT</a>) stock decreased by 9.29% to $0.21. The company's market cap stands at $9.8 million. </li>
<li>AnPac Bio-Medical Science (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANPC#NASDAQ">ANPC</a>) stock decreased by 8.33% to $0.14. The market value of their outstanding shares is at $5.4 million. </li>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) stock decreased by 6.18% to $1.67. The market value of their outstanding shares is at $37.9 million. </li>
<li>AlerisLife (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALR#NASDAQ">ALR</a>) stock declined by 6.02% to $1.25. Trading volume for this security closed at 60.0K, accounting for 49.6% of its average full-day volume over the last 100 days. The company's market cap stands at $40.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AGTC

ANPC

BIMI

CGTX

CHNG

CLXT

LPCN

RSLS

VIRI

12 Health Care Stocks Moving In Monday's After-Market Session

<a href="https://pro.benzinga.com/?utm_source=insights">According to data from Benzinga Pro,</a> during Q2, LogicBio Therapeutics's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) reported sales totaled $3.20 million. Despite a 24.29% increase in earnings, the company posted a loss of $5.04 million. In Q1, LogicBio Therapeutics brought in $2.82 million in sales but lost $6.66 million in earnings. 
<h3>What Is ROCE?</h3>
Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q2, LogicBio Therapeutics posted an ROCE of -0.24%.
It is important to keep in mind that ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but does not account for factors that could affect earnings and sales in the near future. 
ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows LogicBio Therapeutics is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth. 
For LogicBio Therapeutics, a negative ROCE ratio of -0.24% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.
<h3>Analyst Predictions</h3>
LogicBio Therapeutics reported Q2 earnings per share at $-0.15/share, which beat analyst predictions of $-0.24/share.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LogicBio Therapeutics's Return On Capital Employed Insights

Russell 3000 rejig: Consumer discretionary stocks GOEV, GCT among added; LOGC, VUZI out

ContextLogic (LOGC) just unveiled an update. The Company has rewarded its CEO, Rishi Bajaj, with a $620,000 bonus for his successful facilitation o...

ContextLogic Enhances Leadership and Streamlines Governance

ContextLogic GAAP EPS of -$0.50

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ContextLogic (NASDAQ:<a href="https://investorplace.com/stock-quotes/logc-stock-quote/">LOGC</a>) just reported results for the second quarter of 2024.<ul><li>ContextLogic reported earnings per share of -50 cents. This was below the analyst estimate for EPS of -6 cents.</li><li>The company reported revenue of $7.00 million.</li><li>This was 302.30% better than the analyst estimate for revenue of $1.74 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/logc-stock-earnings-contextlogic-for-q2-of-2024/">LOGC Stock Earnings: ContextLogic Misses EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Comments

ContextLogic

Notizie

Ultime notizie per ContextLogic (NASDAQ:LOGC) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO